Updating results

8 results for Anakinra

Sort: Relevance | Date

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

Evidence-based recommendations on tocilizumab (RoActemra) for treating systemic juvenile idiopathic arthritis

Technology appraisal guidance Published December 2011

Rheumatoid arthritis in adults: management (NG100)

This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.

NICE guideline Published July 2018

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014

Past appeals and decisions

use) appeal decision 29 September 2008 TA072 Rheumatoid arthritis - anakinra 18 September 2003 TA375 Rheumatoid arthritis - adalimumab,...

Published May 2019 Last updated May 2019

Block scoping reports

This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.

Published July 2019 Last updated July 2019

The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

This appraisal has been updated and replaced by NICE guideline CG79

Technology appraisal guidance Published November 2003

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016